/PRNewswire/ Duality Biotherapeutics, Inc. ("Duality" or "the Company") today announced the appointment of Dr. Antoine Yver as Chairman of SAB. Dr. Antoine.
At its meeting on February 22, 2022, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on May 3, 2022, the renewal of the mandates of Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp and the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors. Melanie Lee and Carole Piwnica will leave the Board of Directors.
Investegate announcements from Sanofi - Aventis Groupe, Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors